Danaher Corporation (DHR)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Strong free cash flow generation of $4.6B annually supports shareholder returns and financial flexibility
• Diversified portfolio across high-growth biotechnology, life sciences, and diagnostics segments with defensive characteristics
• Solid balance sheet with manageable 0.37 D/E ratio and Altman Z-Score of 3.74 indicating financial stability
• Consistent profitability with 17.51% net margins in latest quarter demonstrating operational execution
• Low beta of 0.96 suggesting stable, less volatile business model relative to market

Concerns

• Valuation is egregiously expensive: P/E of 37.57, EV/EBITDA of 75.89x, with Graham Number suggesting 274% overvaluation
• Weak return metrics with ROE of 7.05% and ROCE of 4.18% indicating capital is not deployed efficiently
• FCF yield of 1.2% is anemic, offering minimal cushion for downturns or disappointing growth
• Piotroski F-Score of 6/9 suggests deteriorating financial health despite near-term profitability

AI Analysis

I've examined Danaher with considerable skepticism. Here's what concerns me: we're paying $198.80 for a stock with a Graham Number of just $53.16, representing a margin of safety of negative 274%. That's not a margin of safety—it's a margin of recklessness. The valuation is severe: a 37.57 P/E ratio, an EV/EBITDA of 75.89x, and a FCF yield of merely 1.2%. These multiples suggest the market has priced in perfection. Now, the business itself isn't without merit. Danaher generates $4.6 billion in free cash flow annually, operates across defensible biotechnology and diagnostics segments, and maintains reasonable financial health with a 0.37 debt-to-equity ratio and a 3.74 Altman Z-Score. The 17.51% net margin in Q4 demonstrates operational competence. However, the ROE of 7.05% and ROCE of 4.18% are disappointing—these returns barely exceed the cost of capital, suggesting management isn't deploying assets with exceptional efficiency. The Piotroski F-Score of 6/9 indicates moderate financial quality, not the fortress balance sheet I demand. With a FairStock Score of only 39/100, this represents speculative territory masquerading as quality. I cannot recommend purchasing at these prices. For value investors adhering to Graham's principles, Danaher presents a classic case of an excellent business trading at an unreasonable price. I would require at least a 50% discount from current levels to consider this an adequate margin of safety.

Bull Case

Danaher's exposure to secular growth trends in biotechnology and diagnostics provides sustained revenue expansion. Strong FCF generation and fortress balance sheet enable strategic acquisitions and shareholder returns, justifying premium multiples if growth accelerates above historical rates.

Bear Case

At 75.89x EV/EBITDA, any slowdown in biotech spending or diagnostics demand could trigger severe multiple compression. Weak ROCE and ROE suggest the company struggles to justify its capital base, risking shareholder value destruction if growth disappoints.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer